EHA 2019 Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed refractory multiple myleoma

EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma

Multiple myeloma is the second most common haematological cancer, and despite significant progress in the past two decades with introduction of several new therapies, the disease remains incurable. Newer therapies targeting disease specific biology is...

More From BioPortfolio on "EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma"